Five-year persistence rates for ACEI therapy varied significantly by indication, ranging from 43.2% for renal disease to 68.2% for myocardial infarction (P < 0.0001).
Observational (n=254,002)
Yes
Long-term persistence with ACE inhibitor therapy varies significantly by clinical indication, with the lowest persistence observed in patients with renal disease and heart failure.
p-value: p=< 0.0001
AIM: Angiotensin-converting enzyme inhibitors (ACEIs) are widely prescribed for several cardiovascular indications. This study investigated patterns of ACEI use for various indications. METHODS: A descriptive, retrospective population-based study was conducted using data from the UK Clinical Practice Research Datalink. Patients starting ACEIs (2007-2014) were selected and ACEI indications were retrieved from electronically recorded medical records. Stratified by indication, we distinguished between persistent and nonpersistent ACEI use, considering a 6-month interval between two prescription periods as a maximum for persistent use. Five-year persistence rates for various indications were calculated using the Kaplan-Meier method and compared in a log-rank test. Nonpersistent users were subdivided into three groups: (i) stop; (ii) restart; and (iii) switch to an angiotensin II-receptor blocker. Patients who received ACEIs for hypertension who switched to other classes of antihypertensive medications were further investigated. RESULTS: In total, 254 002 ACEI initiators were identified with hypertension (57.6%), myocardial infarction (MI; 4.2%), renal disease (RD; 3.7%), heart failure (HF; 1.5%), combinations of the above (17.2%) or none of the above (15.8%). Five-year persistence rates ranged from 43.2% (RD) to 68.2% (MI; P < 0.0001). RD and HF patients used ACEIs for the shortest time (average 23.6 and 25.0 months, respectively). For the nonpersistent group, the percentage of switchers to angiotensin II-receptor blockers ranged from 27.6% (RD) to 42.2% (MI) and the restarters ranged from 15.0% (HF) to 18.1% (group without indication). CONCLUSIONS: Depending on the indication, there are various rates of ACEI nonpersistence. Patients with RD are most likely to discontinue treatment.
Mahmoudpour et al. (Tue,) conducted a observational in Cardiovascular indications (hypertension, myocardial infarction, renal disease, heart failure) (n=254,002). Angiotensin-converting enzyme inhibitors (ACEIs) vs. Comparison across different indications was evaluated on Five-year persistence rates (p=< 0.0001). Five-year persistence rates for ACEI therapy varied significantly by indication, ranging from 43.2% for renal disease to 68.2% for myocardial infarction (P < 0.0001).